Premium
Relatively favorable outcomes of post‐transplant pulmonary function in patients with chronic myeloid leukemia receiving non‐myeloablative allogeneic hematopoietic stem cell transplantation
Author(s) -
Lee M. Y.,
Chiou T. J.,
Yang M. H.,
Bai L. Y.,
Hsiao L. T.,
Chao T. C.,
Tung S. L.,
Wang W. S.,
Yen C. C.,
Liu J. H.,
Chen P. M.
Publication year - 2005
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2004.00366.x
Subject(s) - medicine , dlco , pulmonary function testing , hematopoietic stem cell transplantation , myeloid leukemia , transplantation , oncology , gastroenterology , diffusing capacity , lung , lung function
Pulmonary function tests were performed in 20 patients with chronic myeloid leukemia before and after human leukocyte antigen‐matched allogeneic sibling hematopoietic stem cell transplantation (HSCT) to identify any conditioning treatment effects on post‐transplant function from January 1995 to December 2002. Of 20 patients, eight received non‐myeloablative conditioning treatment and 12 received conventional myeloablative conditioning treatment. Pulmonary function tests including forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), and diffusion capacity for carbon monoxide (DLCO) were performed pretransplant, 6 and 12 months post‐transplant. Possible pre‐HSCT and post‐HSCT risk factors were evaluated for association with pulmonary function. The results showed that myeloablative conditioning treatment had greater negative impact on FEV1, FVC, and DLCO than non‐myeloablative conditioning therapy. We conclude that non‐myeloablative allogeneic HSCT may apply a better transplant choice in patients who need special concern with post‐transplant pulmonary function changes.